Marketed Products

A genetic test for hereditary breast and ovarian cancer

BRACAnalysis® assesses a woman's risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer and is reimbursed by insurance.

A genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)

COLARIS® is a predictive medicine test for hereditary colorectal and endometrial cancer (hereditary nonpolyposis colorectal cancer, HNPCC). COLARIS® detects disease-causing mutations in three genes, MLH1, MSH2, and MSH6, which are responsible for the majority of HNPCC.

A genetic test for adenomatous polyposis syndromes

COLARIS AP® is a predictive medicine product for risk of hereditary colorectal polyps and cancer. COLARIS AP® detects mutations in the APC and MYH genes, which cause adenomatous polyposis syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MYH -associated polyposis (MAP).

A genetic test for hereditary melanoma

MELARIS® is a predictive medicine test for inherited susceptibility to melanoma and pancreatic cancer. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which occur in up to 40% of families with hereditary melanoma. Patient survival is excellent when melanoma is detected at an early stage; however, prognosis is very poor (<15% 5-year survival) when melanoma has spread at the time of diagnosis. Early detection of melanoma is perhaps the best approach to improve outcome.

A test to predict toxicity to 5-FU/capecitabine-based chemotherapy

TheraGuide 5-FU™ is the most comprehensive test available for assessing the risk of toxicity due to 5-FU/capecitabine-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy. TheraGuide 5-FU™ is a simple blood test that provides comprehensive analysis of DPYD and TYMS gene variations to predict and help prevent 5-FU-related adverse events.